Collegium Pharmaceutical, Inc. (COLL) financial statements (2020 and earlier)

Company profile

Business Address 100 TECHNOLOGY CENTER DRIVE
STOUGHTON, MA 02072
State of Incorp. VA
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments15414711915396
Cash and cash equivalents15414711915396
Receivables8478102 
Inventory, net of allowances, customer advances and progress billings9821 
Inventory9821 
Prepaid expense 3111
Deferred costs    0
Other current assets 1000
Other undisclosed current assets3111 
Total current assets:25023813315997
Noncurrent Assets
Operating lease, right-of-use asset9
Property, plant and equipment129211
Intangible assets, net (including goodwill), including:3344 2 
Other undisclosed intangible assets, net (including goodwill)3344 2 
Restricted cash and investments  000
Other noncurrent assets0000 
Total noncurrent assets:5454231
TOTAL ASSETS:30429113616298
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities334314186
Accounts payable1212694
Accrued liabilities2131992
Debt42 33
Other undisclosed current liabilities165145175 
Total current liabilities:20118931268
Noncurrent Liabilities
Long-term debt and lease obligation1810 14
Long-term debt, excluding current maturities910 14
Operating lease, liability10
Liabilities, other than long-term debt 1 00
Deferred revenue and credits 00
Other liabilities 1   
Total noncurrent liabilities:1811 24
Total liabilities:220200312713
Stockholders' equity
Stockholders' equity attributable to parent, including:849210413585
Common stock00000
Additional paid in capital442429402358214
Accumulated deficit(358)(337)(298)(223)(129)
Other undisclosed stockholders' equity attributable to parent    (0)
Total stockholders' equity:849210413585
TOTAL LIABILITIES AND EQUITY:30429113616298

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues296280282 
Revenue, net282 
Cost of revenue
(Cost of Goods and Services Sold)
(174)(166)(3)(0) 
Gross profit:122115261 
Operating expenses(132)(135)(101)(96)(27)
Other undisclosed operating income   0 
Operating loss:(10)(21)(75)(94)(27)
Nonoperating income (expense)221(0)(0)
Investment income, nonoperating22   
Other nonoperating income (expense)  1(0)(0)
Interest and debt expense(3)(20) (0)0
Net loss:(11)(39)(75)(94)(27)
Other undisclosed net income (loss) attributable to parent   0(0)
Net loss available to common stockholders, diluted:(11)(39)(75)(94)(27)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(11)(39)(75)(94)(27)
Comprehensive loss, net of tax, attributable to parent:(11)(39)(75)(94)(27)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: